Yarrow Bioscience
YARW
31 hedge funds and large institutions have $16.1M invested in Yarrow Bioscience in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
17% more capital inflows, than outflows
Capital inflows: $2.34M | Capital outflows: $2M
3% more funds holding
Funds holding: 30 → 31 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.66% less ownership
Funds ownership: 55.57% → 54.91% (-0.66%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Silverarc Capital Management
Boston,
Massachusetts
|
+$950K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$932K |
| 3 |
ADAR1 Capital Management
Austin,
Texas
|
+$152K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$74.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$71.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$876K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$426K |
| 3 |
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$335K |
| 4 |
Exome Asset Management
New York
|
-$155K |
| 5 |
Prelude Capital Management
New York
|
-$73.7K |
YARW Hedge Fund Activity: Q2 2024 in Review
31 of the 6,944 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q2 2024, worth a combined $16.1M — down 30% from $22.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new YARW positions and 2 closed out — a net gain of 1 holder — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Silverarc Capital Management, adding an estimated $950K. The largest seller was Parkman Healthcare Partners, cutting an estimated $876K.
- 31 institutional investors held Yarrow Bioscience (YARW) as of Q2 2024, up from 30 in Q1 2024.
- Funds reported $16.1M of Yarrow Bioscience stock for Q2 2024, down 30% quarter-over-quarter.
- 3 funds opened new Yarrow Bioscience positions in Q2 2024 and 2 closed out, a net change of +1 holder.
- The largest Yarrow Bioscience buyer in Q2 2024 was Silverarc Capital Management, an estimated $950K added.
- The largest Yarrow Bioscience seller in Q2 2024 was Parkman Healthcare Partners, an estimated $876K sold.
Based on aggregated 13F filings for Q2 2024.